Advertisement

Exosomes for Immunotherapy of Cancer

  • Nathalie Chaput
  • N. E. C. Schartz
  • Fabrice Andre
  • Laurence ZitvogelEmail author
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 532)

Abstract

Exosomes are 60 to 90 nm membrane vesicles originating from late endosomes and secreted from most hematopoietic and epithelial cells in vitro. B cell derived-exosome antigenicity was first reported in 1996 in MHC class II restricted CD4+ T lymphocytes. In 1998, we reported that dendritic cell derived-exosomes are immunogenic in mice leading to tumor rejection. These findings have renewed the interest in exosomes. The current challenge consists in understanding the mechanisms and the physiological relevance of exosomes that could contribute to the design of the optimal exosome based-vaccination. Here, we will focus on the biological features pertaining to dendritic cell-and tumor cell derived-exosomes and will discuss their potential clinical implementation.

Keywords

Tumor Antigen Late Endosome Tumor Rejection Malignant Effusion Tumor Rejection Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Denzer, K., et al. Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 2000; 113: 3365–74.PubMedGoogle Scholar
  2. 2.
    Denzer, K. et al. Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J Immunol 2000; 165: 1259–65.PubMedGoogle Scholar
  3. 3.
    Quah, B. and ONeill, H.C. The application of dendritic cell-derived exosomes in tumour immunotherapy. Cancer Biotherapy and Radiopharm 2000; 15: 185–194.CrossRefGoogle Scholar
  4. 4.
    André, F. et al. Malignant effusions and immunogenic tumor derived-exosomes. The Lancet 2002; 360: 295–305.CrossRefGoogle Scholar
  5. 5.
    Zitvogel, L. et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med 1998:4: 594–600.PubMedCrossRefGoogle Scholar
  6. 6.
    Wolfers, J. et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med 2001;7: 297–303.PubMedCrossRefGoogle Scholar
  7. 7.
    Johnstone, R. M.et al. Vesicle formation during reticulocyte maturation. Association of plasma membrane activities with released vesicles (exosomes). J. Biol. Chem 1987; 262: 9412–9420.PubMedGoogle Scholar
  8. 8.
    Raposo, G. et al. Accumulation ofmajor histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. Molec. Biol. Cell 1997; 8: 2631–2645.Google Scholar
  9. 9.
    Escola, J. M. et al. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. Journal of Biological Chemistry 1998;273;20121–7.PubMedCrossRefGoogle Scholar
  10. 10.
    Arnold, P.Y. and Mannie, M.D. Vesicles bearing MHC class II molecules mediate transfer of antigen-presenting cells to CD4+ cells. Eur. J. Immunol 1999;29:1363–1373.Google Scholar
  11. 11.
    Heijnen, I. A. et al. Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice, Journal of Clinical Investigation 1996; 97: 331–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Hess, C. et al. Ectosomes released by human neutrophils are specialized functional units. J Immunol 1999;163: 4564–73.PubMedGoogle Scholar
  13. 13.
    Patel, D. et al. Class II MHC/peptide complexes are released from APC and are acquired by T cell responders during specific antigen recognition. J Immunol 1999;163: 5201–10.PubMedGoogle Scholar
  14. 14.
    Geminard, C. et al. Characteristics of the Interaction between Hsc70 and the transferrin receptor in exosomes released during reticulocyte maturation. J. Biol. Chem. 2001;276: 9910–9916.PubMedCrossRefGoogle Scholar
  15. 15.
    Skokos, D. et al. Mast cell-dependent B and T lymphocyte activation is mediated by the secretion of immunologically active exosomes. J Immunol 2001;166: 868–76.PubMedGoogle Scholar
  16. 16.
    .Thery, C. et al. Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 1999;147: 599–610.PubMedCrossRefGoogle Scholar
  17. 17.
    Thery, C. et al. Proteomic analysis of dendritic cell-derived exosomes: a secreted subcellular compartment distinct from apoptotic vesicles. J Immunol 2001;166: 7309–18.PubMedGoogle Scholar
  18. 18.
    Clayton, A. et al. Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods 2001;247: 163–74.PubMedCrossRefGoogle Scholar
  19. 19.
    Raposo, G. et al. B lymphocytes secrete antigen-presenting vesicles. J. Exp. Med. 1996;183: 11611172.Google Scholar
  20. 20.
    Blanchard, N. et al. TCR activation of human T cells induces the production of exosomes bearing the TCR/CD3/z complex. J. Immunol 2002;168: 3235–3242.PubMedGoogle Scholar
  21. 21.
    Hanayama, R. et al. Identification of a factor that links apoptotic cells to phagocytes. Nature 2002 May 9;417:182–7.PubMedCrossRefGoogle Scholar
  22. 22.
    van Niel, G. et al. Intestinal epithelial cells secrete exosome-like vesicles. Gastroenterology 2001;121: 337–49.PubMedCrossRefGoogle Scholar
  23. 23.
    Heijnen, H. F., Schiel, A. E., Fijnheer, R., Geuze, H. J. & Sixma, J. J. Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. Blood 1999; 94, 3791–9.PubMedGoogle Scholar
  24. 24.
    Lamparski H. et al. Production and characterization of clinical grade exosomes derived from dendritic cells. J. Immunol. Methods, 2002; 270: 211.PubMedCrossRefGoogle Scholar
  25. 25.
    Pan, B.T. et al. Electron microscopic evidence for externalization of the transferrin receptor in vesicular form in sheep reticulocytes. J. Cell Biol. 1985;101: 942–948.PubMedCrossRefGoogle Scholar
  26. 26.
    Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nature Review Immunol. 2002; 2: 569–579.Google Scholar
  27. 27.
    Théry C, Duban L, Segura E, Véron P, Lantz O, Amigorena S. Exosomes activate naive CD4+ T cells by transfer of MHC/peptide complexes to dendritic cells. Nat. Immunol. In press.Google Scholar
  28. 28.
    Vincent-Schneider H., Stumptner-Cuvelette P., Lanka D., Pain S., Raposo G., Benaroch P., and Bonnerot C. Exosomes bearing HLA-DR1 molecules need dendritic cells to efficiently stimulate specific T cells. Int Immunol. 2002; 14, 713–722.PubMedCrossRefGoogle Scholar
  29. 29.
    Escudier B, Dorval T, Angevin E, Boccaccio C, Robert C, Avril MF, Lantz O, Bonnerot C, Tursz T, Dhellin O, Serra V, Valente N, Le-Pecq JB, Zitvogel L. Novel approach to immunotherapy of cancer: Phase I trial of dexosome vaccine for patients with advanced melanoma. Proc. Am. Soc. Clin. Oncol. 2002; A1857.Google Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Nathalie Chaput
    • 1
  • N. E. C. Schartz
    • 1
    • 2
  • Fabrice Andre
    • 1
  • Laurence Zitvogel
    • 1
    Email author
  1. 1.ERIT-M 02-08 INSERM, Department of Clinical BiologyInstitut Gustave Roussy (IGR)VillejuifFrance
  2. 2.Department of Dermatology 2AP-HP Hôpital Saint -LouisParisFrance

Personalised recommendations